Search

Christopher S Siedem

from Longmont, CO
Age ~59
Get Report
Also known as:
Christopher Stephen Siedem, Christoph S Siedem, Christpher S Siedem, Christophe S Siedem, Chris Siedem, Ieem S Christopher
Phone and address:
4215 Redmond Dr, Longmont, CO 80503
(303) 485-5142
Connected to:
Barbara J Siedenburg, 78Frederick J Siedenburg, 77James A Siederman, 41Patrick J Sieders, 55Ashley M Siedhoff, 41Colten J Siedlarczyk, 34Steven Siedlarz, 35Alex A Siedlecki, 37Denise M Siedlecki, 52Jamie E Siedle, 36

Christopher Siedem Phones & Addresses

  • 4215 Redmond Dr, Longmont, CO 80503 (303) 485-5142 (303) 682-4395 (720) 249-4078
  • Broomfield, CO
  • Rapid City, SD
  • 705 Meadowbank Rd, Kennett Square, PA 19348
  • Gap, PA
  • Center Moriches, NY
  • Evergreen, CO
  • Wilmington, DE
  • Superior, CO
  • Boulder, CO
  • 4215 Redmond Dr, Longmont, CO 80503

Work

Company: Medicinal chemistry Oct 2002 Position: Research investigator

Education

School / High School: University of Colorado- Boulder, CO Sep 1987 Specialities: Chemistry

Emails

c***[email protected]

Resumes

Resumes

Christopher Siedem Photo 1

Research Investigator At Array Biopharma

View page
Location:
Greater Denver Area
Industry:
Pharmaceuticals
Christopher Siedem Photo 2

Christopher Siedem

View page
Location:
United States
Christopher Siedem Photo 3

Christopher Siedem Longmont, CO

View page
Work:
Medicinal Chemistry

Oct 2002 to Jul 2011
Research Investigator
Medicinal Chemistry

Jul 2000 to Oct 2002
Senior Research Scientist
Medicinal Chemistry

Aug 1996 to Jul 2000
Senior Research Scientist
Ariad Pharmaceuticals, Inc

Jun 1994 to Aug 1996
Research Scientist
University of California
Los Angeles, CA
Sep 1987 to Jan 1992
Teaching Assistant
Education:
University of Colorado
Boulder, CO
Sep 1987 to Jun 1994
Chemistry
University of California
Los Angeles, CA
Jan 1992
Ph. D. in Chemistry
Haverford College
Haverford, PA
May 1987
B. S. in Chemistry

Publications

Us Patents

Fused Heterocyclic Compounds

View page
US Patent:
8163935, Apr 24, 2012
Filed:
Apr 26, 2006
Appl. No.:
11/919435
Inventors:
Kazuyoshi Aso - Osaka, JP
Michiyo Mochizuki - Osaka, JP
Albert Charles Gyorkos - Westminster CO, US
Christopher Peter Corrette - Boulder CO, US
Suk Young Cho - Gyeonggi-Do, KR
Scott Alan Pratt - Boulder CO, US
Christopher Stephen Siedem - Boulder CO, US
Assignee:
Takeda Pharmaceutical Company Limited - Osaka
International Classification:
C07D 403/02
C07D 235/24
C07D 235/26
C07D 235/30
A61K 31/415
US Classification:
5483061, 5483064, 5483074, 514395
Abstract:
There is provided a CRF receptor antagonist comprising a compound of the formula (I):.

6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[D]Azepines As 5-Htreceptor Agonist

View page
US Patent:
8580780, Nov 12, 2013
Filed:
Jul 28, 2011
Appl. No.:
13/192707
Inventors:
John Gordon Allen - Newbary Park CA, US
Karin Briner - Indianapolis IN, US
Christopher Stanley Galka - Carmel IN, US
Maria Angeles Martinez-Grau - Madrid, ES
Matthew Robert Reinhard - Indianapolis IN, US
Michael John Rodriguez - Indianapolis IN, US
Roger Ryan Rothhaar - Reelsville IN, US
Michael Wade Tidwell - Lakehills TX, US
Frantz Victor - Indianapolis IN, US
Deyi Zhang - Carmel IN, US
Steven Armen Boyd - Longmont CO, US
Arundhati S. Deo - St. Paul MN, US
Wai-Man Lee - Mateo CA, US
Christopher Stephen Siedem - Longmont CO, US
Ajay Singh - Aurora CO, US
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61P 3/04
A61P 25/22
A61P 25/24
A61P 25/30
A61K 31/55
C07D 223/16
C07D 401/12
C07D 417/12
C07D 413/12
C07D 403/12
C07D 409/12
C07D 405/12
C07D 413/14
C07D 417/06
C07D 403/06
US Classification:
51421701, 540594
Abstract:
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:.

Cyclic Compounds

View page
US Patent:
20070179165, Aug 2, 2007
Filed:
Apr 6, 2005
Appl. No.:
10/593891
Inventors:
Albert Gyorkos - Westminster CO, US
Christopher Corrette - Boulder CO, US
Suk Cho - Boulder CO, US
Timothy Turner - Boulder CO, US
Kazuyoshi Aso - Osaka, JP
Masakuni Kori - Osaka, JP
Michiyo Mochizuki - Osaka, JP
Kevin Condroski - Boulder CO, US
Christopher Siedem - Boulder CO, US
Steven Boyd - Boulder CO, US
International Classification:
A61K 31/44
A61K 31/513
C07D 239/22
US Classification:
514269000, 514345000, 544319000, 546290000
Abstract:
There is provided a CRF receptor antagonist comprising a compound of the formula (I):A-W—Ar  (I)wherein, A is a group represented by the formula (A1) or (A2):

6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines As 5-Ht2C Receptor Agonists

View page
US Patent:
20090099155, Apr 16, 2009
Filed:
Sep 9, 2005
Appl. No.:
10/598302
Inventors:
John Gordon Allen - Indianapolis IN, US
Karin Briner - Indianapolis IN, US
Michael Philip Cohen - Indianapolis IN, US
Christopher Stanley Galka - Carmel IN, US
Sarah Lynne Hellman - Indianapolis IN, US
Maria Angeles Martinez-Grau - Alcobendas(Madrid), ES
Matthew Robert Reinhard - Indianapolis IN, US
Michael John Rodriguez - Indianapolis IN, US
Roger Ryan Rothaar - Reelsville IN, US
Michael Wade Tidwell - Indianapolis IN, US
Frantz Victor - Indianapolis IN, US
Andrew Caerwyn Williams - Hampshire, GB
Deyi Zhang - Carmel IN, US
Steven Armen Boyd - Longmont CO, US
Richard Gerard Conway - Carmel IN, US
Arundhati S. Deo - Saint Paul MN, US
Wai-Man Lee - Longmont CO, US
Christopher Stephen Siedem - Longmont CO, US
Ajay Singh - Aurora CO, US
Michael Philip Mazanetz - Notts, GB
International Classification:
A61K 31/55
C07D 223/16
C07D 417/12
C07D 401/12
A61P 3/04
A61P 25/22
C07D 409/12
C07D 403/12
C07D 405/12
US Classification:
51421701, 540594
Abstract:
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:where:

Fused Heterocyclic Compounds And Their Use As Mineralocorticoid Receptor Ligands

View page
US Patent:
20090253687, Oct 8, 2009
Filed:
Dec 27, 2006
Appl. No.:
12/087148
Inventors:
Shoji Fukumoto - Osaka, JP
Nobuyuki Matsunaga - Osaka, JP
Taiichi Ohra - Osaka, JP
Norio Ohyabu - Osaka, JP
Tomoaki Hasui - Osaka, JP
Takashi Motoyaji - Osaka, JP
Christopher Stephen Siedem - Boulder CO, US
Tony Pisal Tang - Boulder CO, US
Lisa A. Demeese - Boulder CO, US
Cassandra Gauthier - Grand Junction CO, US
International Classification:
A61K 31/542
C07D 285/16
C07D 265/36
A61K 31/538
C07D 279/16
A61K 31/5415
C07D 513/02
A61P 9/00
US Classification:
5142228, 544 10, 544105, 5142305, 544 51, 5142242, 544 73, 544 48
Abstract:
The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.

Pyrazole Compounds

View page
US Patent:
20100094000, Apr 15, 2010
Filed:
Sep 2, 2009
Appl. No.:
12/552701
Inventors:
Shoji FUKUMOTO - Osaka-shi, JP
Norio OHYABU - Osaka-shi, JP
Taiichi OHRA - Osaka-shi, JP
Takahiro SUGIMOTO - Osaka-shi, JP
Tomoaki HASUI - Osaka-shi, JP
Koji FUJI - Osaka-shi, JP
Christopher S. SIEDEM - Boulder CO, US
Cassandra GAUTHIER - Boulder CO, US
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED - Osaka
International Classification:
C07D 417/10
US Classification:
544105
Abstract:
The present invention relates towherein each symbol is as defined in the specification. The compound has a superior mineralocorticoid receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of a disease or condition mediated by the mineralocorticoid receptor activation.

Serine/Threonine Kinase Inhibitors

View page
US Patent:
20130338140, Dec 19, 2013
Filed:
Feb 28, 2012
Appl. No.:
14/002079
Inventors:
James F. Blake - Boulder CO, US
Huifen Chen - South San Francisco CA, US
Jason Demeese - Boulder CO, US
Rustam Garrey - Boulder CO, US
John J. Gaudino - Boulder CO, US
Robert J. Kaus - Boulder CO, US
Gabrielle R. Kolakowski - Boulder CO, US
Allison L. Marlow - Boulder CO, US
Peter J. Mohr - Boulder CO, US
Li Ren - Boulder CO, US
Jacob Schwartz - South San Francisco CA, US
Christopher S. Siedem - Boulder CO, US
Allen A. Thomas - Boulder CO, US
Eli Wallace - Boulder CO, US
Steven Mark Wenglowsky - Boulder CO, US
Assignee:
Genetech, Inc. - South San Francisco CA
Array BioPharma Inc. - Boulder CO
International Classification:
C07D 471/04
A61K 45/06
A61K 31/519
US Classification:
51421021, 544279, 51426411, 435184
Abstract:
Compounds having the formula I wherein Z, ZZZ, R, Rand Rand as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

Quinazoline Compounds As Serine/Threonine Kinase Inhibitors

View page
US Patent:
20150087664, Mar 26, 2015
Filed:
Aug 3, 2012
Appl. No.:
14/237143
Inventors:
James F. Blake - Boulder CO, US
Huifen Chen - South San Francisco CA, US
Mark Joseph Chicarelli - Boulder CO, US
Jason Demeese - Boulder CO, US
Rustam Ferdinand Garrey - Boulder CO, US
John Gaudino - Boulder CO, US
Lewis Gazzard - South San Francisco CA, US
Robert J. Kaus - Boulder CO, US
Samuel Kintz - South San Francisco CA, US
Peter J. Mohr - Boulder CO, US
David A. Moreno - Boulder CO, US
Jacob Schwartz - South San Francisco CA, US
Christopher S. Siedem - Boulder CO, US
Eli M. Wallace - Boulder CO, US
Assignee:
GENENTECH, INC. - South San Francisco CA
ARRAY BIOPHARMA INC. - Boulder CO
International Classification:
C07D 405/14
C07D 403/12
US Classification:
51426623, 544284, 544292, 51426624
Abstract:
Compounds having the formula (I) wherein R, R, Rand Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
Control profile
Christopher S Siedem from Longmont, CO, age ~59 Get Report